Advertisement
American Journal of Kidney Diseases

Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment

Published:March 04, 2016DOI:https://doi.org/10.1053/j.ajkd.2015.12.033
      Acute kidney injury (AKI) is a serious complication, commonly occurring in the critically ill population, with devastating short- and long-term consequences. Despite standardization of the definition and staging of AKI, early recognition remains challenging given that serum creatinine level is a marker, albeit imperfect, of kidney function and not kidney injury. Furthermore, the delay in increase in serum creatinine level after loss of glomerular filtration also prevents timely detection of decreased kidney function in patients with AKI. During the past decade, numerous clinical investigations have evaluated the utility of several biomarkers in the early diagnosis and risk stratification of AKI. In 2014, the US Food and Drug Administration approved the marketing of a test based on the combination of urine concentrations of tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7 ([TIMP-2] × [IGFBP7]) to determine whether certain critically ill patients are at risk for developing moderate to severe AKI. The optimal role of this biomarker in the diagnosis, management, and prognosis of AKI in different clinical settings requires further clarification. In this perspective, we summarize the biological actions of these 2 cell-cycle arrest biomarkers and present important considerations regarding the clinical application, interpretation, and limitations of this novel test for the early detection of AKI.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chawla L.S.
        • Amdur R.L.
        • Shaw A.D.
        • Faselis C.
        • Palant C.E.
        • Kimmel P.L.
        Association between AKI and long-term renal and cardiovascular outcomes in United States veterans.
        Clin J Am Soc Nephrol. 2014; 9: 448-456
        • Chertow G.
        • Levy E.
        • Hammermeister K.
        • Grover F.
        • Daley J.
        Independent association between acute renal failure and mortality following cardiac surgery.
        Am J Med. 1998; 104: 343-348
        • Uchino S.
        • Kellum J.A.
        • Bellomo R.
        • et al.
        Acute renal failure in critically ill patients: a multinational, multicenter study.
        JAMA. 2005; 294: 813-818
        • Koyner J.L.
        • Cerda J.
        • Goldstein S.L.
        • et al.
        The daily burden of acute kidney injury: a survey of US nephrologists on World Kidney Day.
        Am J Kidney Dis. 2014; 64: 394-401
        • American Society of Nephrology
        The American Society of Nephrology renal research report.
        J Am Soc Nephrol. 2005; 16: 1886-1903
        • Moran S.M.
        • Myers B.D.
        Course of acute renal failure studied by a model of creatinine kinetics.
        Kidney Int. 1985; 27: 928-937
        • Waikar S.S.
        • Betensky R.A.
        • Emerson S.C.
        • Bonventre J.V.
        Imperfect gold standards for kidney injury biomarker evaluation.
        J Am Soc Nephrol. 2012; 23: 13-21
        • Parikh C.R.
        • Devarajan P.
        • Zappitelli M.
        • et al.
        Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery.
        J Am Soc Nephrol. 2011; 22: 1737-1747
        • Parikh C.R.
        • Coca S.G.
        • Thiessen-Philbrook H.
        • et al.
        Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery.
        J Am Soc Nephrol. 2011; 22: 1748-1757
        • Siew E.D.
        • Ware L.B.
        • Gebretsadik T.
        • et al.
        Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults.
        J Am Soc Nephrol. 2009; 20: 1823-1832
        • Kashani K.
        • Al-Khafaji A.
        • Ardiles T.
        • et al.
        Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury.
        Crit Care. 2013; 17: R25
        • Nickolas T.L.
        • Schmidt-Ott K.M.
        • Canetta P.
        • et al.
        Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study.
        J Am Coll Cardiol. 2012; 59: 246-255
      1. US Food and Drug Administration. News release “FDA allows marketing of the first test to assess risk of developing acute kidney injury.” September 5, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412910.htm. Accessed May 11, 2015.

        • Bihorac A.
        • Chawla L.S.
        • Shaw A.D.
        • et al.
        Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication.
        Am J Respir Crit Care Med. 2014; 189: 932-939
        • Seo D.W.
        • Li H.
        • Guedez L.
        • et al.
        TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism.
        Cell. 2003; 114: 171-180
        • Seo D.W.
        • Li H.
        • Qu C.K.
        • et al.
        Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells.
        J Biol Chem. 2006; 281: 3711-3721
        • Barasch J.
        • Yang J.
        • Qiao J.
        • et al.
        Tissue inhibitor of metalloproteinase-2 stimulates mesenchymal growth and regulates epithelial branching during morphogenesis of the rat metanephros.
        J Clin Invest. 1999; 103: 1299-1307
        • Engers R.
        • Springer E.
        • Michiels F.
        • Collard J.G.
        • Gabbert H.E.
        Rac affects invasion of human renal cell carcinomas by up-regulating tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP-2 expression.
        J Biol Chem. 2001; 276: 41889-41897
        • Hwa V.
        • Oh Y.
        • Rosenfeld R.G.
        The insulin-like growth factor-binding protein (IGFBP) superfamily.
        Endocr Rev. 1999; 20: 761-787
        • Wajapeyee N.
        • Kapoor V.
        • Mahalingam M.
        • Green M.R.
        Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines.
        Mol Cancer Ther. 2009; 8: 3009-3014
        • Zuo S.
        • Liu C.
        • Wang J.
        • et al.
        IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells.
        J Cancer Res Clin Oncol. 2012; 138: 1045-1055
        • Liu Y.
        • Guo W.
        • Zhang J.
        • et al.
        Urinary interleukin 18 for detection of acute kidney injury: a meta-analysis.
        Am J Kidney Dis. 2013; 62: 1058-1067
        • Vanmassenhove J.
        • Vanholder R.
        • Nagler E.
        • Van Biesen W.
        Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature.
        Nephrol Dial Transplant. 2013; 28: 254-273
        • Ostermann M.
        • Philips B.J.
        • Forni L.G.
        Clinical review: biomarkers of acute kidney injury: where are we now?.
        Crit Care. 2012; 16: 233
        • Wasung M.E.
        • Chawla L.S.
        • Madero M.
        Biomarkers of renal function, which and when?.
        Clin Chim Acta. 2015; 438: 350-357
        • Charlton J.R.
        • Portilla D.
        • Okusa M.D.
        A basic science view of acute kidney injury biomarkers.
        Nephrol Dial Transplant. 2014; 29: 1301-1311
        • Koyner J.L.
        • Parikh C.R.
        Clinical utility of biomarkers of AKI in cardiac surgery and critical illness.
        Clin J Am Soc Nephrol. 2013; 8: 1034-1042
        • de Geus H.R.
        • Betjes M.G.
        • Bakker J.
        Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges.
        Clin Kidney J. 2012; 5: 102-108
        • Gonzalez F.
        • Vincent F.
        Biomarkers for acute kidney injury in critically ill patients.
        Minerva Anestesiol. 2012; 78: 1394-1403
        • Herget-Rosenthal S.
        • Metzger J.
        • Albalat A.
        • Bitsika V.
        • Mischak H.
        Proteomic biomarkers for the early detection of acute kidney injury.
        Prilozi. 2012; 33: 27-48
        • Hoste E.A.
        • McCullough P.A.
        • Kashani K.
        • et al.
        Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers.
        Nephrol Dial Transplant. 2014; 29: 2054-2061
        • Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group
        Clinical practice guideline for acute kidney injury.
        Kidney Int Suppl. 2012; : 1-138
        • Xia J.
        • Broadhurst D.I.
        • Wilson M.
        • Wishart D.S.
        Translational biomarker discovery in clinical metabolomics: an introductory tutorial.
        Metabolomics. 2013; 9: 280-299
        • Pickering J.W.
        • James M.T.
        • Palmer S.C.
        Acute kidney injury and prognosis after cardiopulmonary bypass: a meta-analysis of cohort studies.
        Am J Kidney Dis. 2015; 65: 283-293
        • Zarbock A.
        • Schmidt C.
        • Van Aken H.
        • et al.
        Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial.
        JAMA. 2015; 313: 2133-2141
        • Meersch M.
        • Schmidt C.
        • Van Aken H.
        • et al.
        Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery.
        PLoS One. 2014; 9: e93460
        • Wetz A.J.
        • Richardt E.M.
        • Wand S.
        • et al.
        Quantification of urinary TIMP-2 and IGFBP-7: an adequate diagnostic test to predict acute kidney injury after cardiac surgery?.
        Crit Care. 2015; 19: 3
        • Meersch M.
        • Schmidt C.
        • Van Aken H.
        • et al.
        Validation of cell-cycle arrest biomarkers for acute kidney injury after pediatric cardiac surgery.
        PLoS One. 2014; 9: e110865
        • Gocze I.
        • Koch M.
        • Renner P.
        • et al.
        Urinary biomarkers TIMP-2 and IGFBP7 early predict acute kidney injury after major surgery.
        PLoS One. 2015; 10: e0120863
        • Chawla L.S.
        • Davison D.L.
        • Brasha-Mitchell E.
        • et al.
        Development and standardization of a furosemide stress test to predict the severity of acute kidney injury.
        Crit Care. 2013; 17: R207
        • Koyner J.L.
        • Davison D.L.
        • Brasha-Mitchell E.
        • et al.
        Furosemide stress test and biomarkers for the prediction of AKI severity.
        J Am Soc Nephrol. 2015; 26: 2023-2031
      2. US Food and Drug Administration. Letter to Astute Medical September 5, 2014. http://www.accessdata.fda.gov/cdrh_docs/pdf13/den130031.pdf. Accessed May 11, 2015.

      3. Astute Medical, Inc. NephroCheck® Test Kit Package Insert. 2014 PN 300152 Rev E 2014/09/05. http://www.astutemedical.com/content/documents/us/NephroCheck_Test_Package_Insert_US_IVD_(PN_300152)_RevE.pdf; Accessed February 5, 2016.

      4. US Food and Drug Administration. Evaluation of automatic class III designation for NephroCheckSystem® test system decision summary. http://www.accessdata.fda.gov/cdrh_docs/reviews/den130031.pdf. Accessed May 11, 2015.

        • Thiele R.H.
        • Isbell J.M.
        • Rosner M.H.
        AKI associated with cardiac surgery.
        Clin J Am Soc Nephrol. 2015; 10: 500-514
        • Lusky K.
        AKI risk biomarkers may be “as early as it gets.”.
        CAP Today. June:12-16, 2015; (Accessed July 10, 2015)
        • Hobson C.
        • Ozrazgat-Baslanti T.
        • Kuxhausen A.
        • et al.
        Cost and mortality associated with postoperative acute kidney injury.
        Ann Surg. 2015; 261: 1207-1214
      5. Section 3: Prevention and treatment of AKI. In: KDIGO clinical practice guideline for acute kidney injury: prevention and treatment of AKI. Kidney Int Suppl. 2012;2:37–68.

        • Flynn N.
        • Dawnay A.
        A simple electronic alert for acute kidney injury.
        Ann Clin Biochem. 2015; 52: 206-212
        • Thomas M.E.
        • Blaine C.
        • Dawnay A.
        • et al.
        The definition of acute kidney injury and its use in practice.
        Kidney Int. 2015; 87: 62-73
        • Wallace K.
        • Mallard A.S.
        • Stratton J.D.
        • Johnston P.A.
        • Dickinson S.
        • Parry R.G.
        Use of an electronic alert to identify patients with acute kidney injury.
        Clin Med. 2014; 14: 22-26
        • Wilson F.P.
        • Shashaty M.
        • Testani J.
        • et al.
        Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial.
        Lancet. 2015; 385: 1966-1974
        • Ponce D.
        • Zorzenon Cde P.
        • dos Santos N.Y.
        • Balbi A.L.
        Early nephrology consultation can have an impact on outcome of acute kidney injury patients.
        Nephrol Dial Transplant. 2011; 26: 3202-3206
        • Mehta R.L.
        • McDonald B.
        • Gabbai F.
        • et al.
        Nephrology consultation in acute renal failure: does timing matter?.
        Am J Med. 2002; 113: 456-461
        • Meier P.
        • Bonfils R.M.
        • Vogt B.
        • Burnand B.
        • Burnier M.
        Referral patterns and outcomes in noncritically ill patients with hospital-acquired acute kidney injury.
        Clin J Am Soc Nephrol. 2011; 6: 2215-2225
        • Balasubramanian G.
        • Al-Aly Z.
        • Moiz A.
        • et al.
        Early nephrologist involvement in hospital-acquired acute kidney injury: a pilot study.
        Am J Kidney Dis. 2011; 57: 228-234
        • Perazella M.A.
        • Coca S.G.
        • Hall I.E.
        • Iyanam U.
        • Koraishy M.
        • Parikh C.R.
        Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients.
        Clin J Am Soc Nephrol. 2010; 5: 402-408
        • Perazella M.A.
        The urine sediment as a biomarker of kidney disease.
        Am J Kidney Dis. 2015; 66: 748-755
        • Tiong H.Y.
        • Huang P.
        • Xiong S.
        • Li Y.
        • Vathsala A.
        • Zink D.
        Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models.
        Mol Pharm. 2014; 11: 1933-1948
        • Perazella M.A.
        Drug use and nephrotoxicity in the intensive care unit.
        Kidney Int. 2012; 81: 1172-1178
        • Jo S.K.
        • Rosner M.H.
        • Okusa M.D.
        Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon.
        Clin J Am Soc Nephrol. 2007; 2: 356-365
        • Bove T.
        • Zangrillo A.
        • Guarracino F.
        • et al.
        Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial.
        JAMA. 2014; 312: 2244-2253
        • Hirschberg R.
        • Kopple J.
        • Lipsett P.
        • et al.
        Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.
        Kidney Int. 1999; 55: 2423-2432
        • Lewis J.
        • Salem M.M.
        • Chertow G.M.
        • et al.
        Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group.
        Am J Kidney Dis. 2000; 36: 767-774
        • Bonventre J.V.
        • Basile D.
        • Liu K.D.
        • et al.
        AKI: a path forward.
        Clin J Am Soc Nephrol. 2013; 8: 1606-1608
        • Soni S.S.
        • Ronco C.
        • Katz N.
        • Cruz D.N.
        Early diagnosis of acute kidney injury: the promise of novel biomarkers.
        Blood Purif. 2009; 28: 165-174
        • Hall I.E.
        • Yarlagadda S.G.
        • Coca S.G.
        • et al.
        IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation.
        J Am Soc Nephrol. 2010; 21: 189-197
        • Koyner J.L.
        • Vaidya V.S.
        • Bennett M.R.
        • et al.
        Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury.
        Clin J Am Soc Nephrol. 2010; 5: 2154-2165
        • Parikh C.R.
        • Jani A.
        • Mishra J.
        • et al.
        Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation.
        Am J Transplant. 2006; 6: 1639-1645
        • Parikh C.R.
        • Mishra J.
        • Thiessen-Philbrook H.
        • et al.
        Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery.
        Kidney Int. 2006; 70: 199-203
        • Portilla D.
        • Dent C.
        • Sugaya T.
        • et al.
        Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery.
        Kidney Int. 2008; 73: 465-472
        • Doi K.
        • Noiri E.
        • Maeda-Mamiya R.
        • et al.
        Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury.
        Crit Care Med. 2010; 38: 2037-2042
        • Susantitaphong P.
        • Siribamrungwong M.
        • Doi K.
        • Noiri E.
        • Terrin N.
        • Jaber B.L.
        Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis.
        Am J Kidney Dis. 2013; 61: 430-439
        • Parr S.K.
        • Clark A.J.
        • Bian A.
        • et al.
        Urinary L-FABP predicts poor outcomes in critically ill patients with early acute kidney injury.
        Kidney Int. 2015; 87: 640-648
        • Torregrosa I.
        • Montoliu C.
        • Urios A.
        • et al.
        Urinary KIM-1, NGAL and L-FABP for the diagnosis of AKI in patients with acute coronary syndrome or heart failure undergoing coronary angiography.
        Heart Vessels. 2015; 30: 703-711
        • Du Y.
        • Zappitelli M.
        • Mian A.
        • et al.
        Urinary biomarkers to detect acute kidney injury in the pediatric emergency center.
        Pediatr Nephrol. 2011; 26: 267-274
        • Liang X.L.
        • Liu S.X.
        • Chen Y.H.
        • et al.
        Combination of urinary kidney injury molecule-1 and interleukin-18 as early biomarker for the diagnosis and progressive assessment of acute kidney injury following cardiopulmonary bypass surgery: a prospective nested case-control study.
        Biomarkers. 2010; 15: 332-339
        • Liangos O.
        • Tighiouart H.
        • Perianayagam M.C.
        • et al.
        Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass.
        Biomarkers. 2009; 14: 423-431